N-Boc-L-tert-Leucine

Product Details

CAS No:62965-35-9

MF:C11H21NO4

Appearance:white or off-white crystalline powder

Specification:98.5%

UN number:-

Package:1/5/10/25kgs/drum

Supply Capacity:MT

Synonyms:BOC-TBU-GLYCINE;BOC-TBU-GLY-OH;BOC-TLE;BOC-ALPHA-BUTYLGLYCINE;BOC-ALPHA-T-BUTYLGLYCINE;BOC-ALPHA-T-BUTYLGLYCINE-OH;BOC-ALPHA-T-BUTYL-GLY-OH;BOC-L-T-BUTYLGLYCINE; N-Boc-L-tert-Leucine; (S)-2-((tert-Butoxycarbonyl)amino)-3,3-dimethylbutanoic acid; n-tert-butoxycarbonyl-l-tert-leucine; L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-; EC 613-118-8; L-Valine, N-((1,1-dimethylethoxy)carbonyl)-3-methyl-; RefChem:407855; 613-118-8; 62965-35-9; Boc-Tle-OH; Boc-L-tert-leucine; (s)-n-(tert-butoxycarbonyl)-tert-leucine; MFCD00065574; N-(tert-Butoxycarbonyl)-L-tert-leucine; Valine, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-; (2S)-3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid; SCHEMBL57432; (2S)-2-{[(tert-butoxy)carbonyl]amino}-3,3-dimethylbutanoic acid; Boc-L-alpha-t-butylglycine; AKOS010366207; AS-14826; HY-59260; N-tert-butyloxycarbonyl-L-tert-butylglycine; EN300-52856; (S)-2-(Boc-amino)-3,3-dimethylbutyric Acid; (s)-2-(tert-butoxycarbonylamino)-3,3-dimethylbutanoic acid; Nirmatrelvir Impurity 21; N-boc-t-leucine; Boc-tert-Leucine; Boc-tLeu-OH; (2S)-2-(tert-Butoxycarbonylamino)-3,3-dimethylbutanoic Acid; (S)-2-(((tert-Butoxy)carbonyl)amino)-3,3-dimethylbutanoic Acid; (S)-2-tert-Butoxycarbonylamino-3,3-dimethylbutyric Acid; N-Boc-L-tert-leucine; N-tert-Butoxycarbonyl-L-tert-butylglycine; Boc-t-Leu-OH; BOC-TBU-GLYCINE; (2S)-2-(tert-butoxycarbonylamino)-3,3-dimethyl-butanoic acid; N-(tert-butoxycarbonyl)-3-methyl-L-valine; BOC-L-TLE-OH; Boc-L-|A-tert-butylglycine; A834127; CHEMBL5305116; SCHEMBL21834858; Boc-L-| cent-tert-butylglycine; CHEBI:231585; tert-butyloxycarbonyl-L-tert-leucine; AKOS015841338; Boc-Tle-OH, >=99.0% (T); CS-W008945; FA31662; tert-butoxycarbonyl-L-tert-butylglycine; AC-24090; PD196040; SY021490; N-(tert-butoxycarbonyl)-L-tert-butyglycine; DB-038170; N-(tert-butoxycarbonyl)-L-tert-butylglycine; B3754; ST50319404; (S)-N-Boc-2-amino-3,3-dimethylbutyric acid; F037101; (2s)-tert-butoxycarbonylamino-3,3-dimethylbutyric acid; 2(S)-tert-butoxycarbonylamino-3,3-dimethyl-butyric acid; F8880-8920; N-{[(1,1-dimethylethyl)oxy]carbonyl}-3-methyl-L-valine; (2S)-2-tert-butoxycarbonylamino-3,3-dimethylbutanoic acid; (S)-2-(tert-Butoxycarbonylamino)-3,3-dimethylbutyric Acid; (2S)-2-[(tert-butoxy)carbonyl]amino-3,3-dimethylbutanoic acid; (2S)-2-[(tert-butoxy)carbonylamino]-3,3-dimethylbutanoic acid; (S)-2-((tert-butoxycarbonyl) amino)-3,3-dimethylbutanoic acid; (S)-2 -[(tert-Butyloxycarbonyl)amino]-3,3-dimethylbutanoic acid

Product application:N-Boc-l-tert-Leucine,62965-35-9,N-(tert-Butoxycarbonyl)-L-tert-leucine,Boc-Tle-OH,Boc-L-tert-leucine,(S)-2-(tert-Butoxycarbonylamino)-3,3-dimethylbutyric acid,Boc-L-alpha-t-butylglycine,Unnatural amino acid derivative,Boc-protected amino acid,Chiral unnatural amino acid,Solid-phase peptide synthesis reagent,SPPS building block,Atazanavir intermediate,Atazanavir related compound A,PROTAC synthon,Chiral oxazoline ligand precursor,Asymmetric catalysis intermediate,Protease inhibitor building block,Antiviral drug intermediate,High purity N-Boc-l-tert-Leucine 99.5%,CAS 62965-35-9 supplier,Boc-Tle-OH manufacturer China,Suzhou Health Chemicals specialty amino acids,N-Boc-L-tert-leucine wholesale bulk export

 

N-Boc-l-tert-Leucine serves as an indispensable, ultra-pure chiral unnatural amino acid derivative, benchmark solid-phase peptide synthesis (SPPS) building block, and versatile pharmaceutical active pharmaceutical ingredient (API) intermediate extensively utilized across antiviral protease inhibitor manufacturing, target protein degradation (PROTAC) discovery, peptide-drug conjugate (PDC) design, and asymmetric catalysis sectors. In peptide chemistry and antiviral medicinal chemistry, universally designated as Boc-Tle-OH or Boc-L-tert-leucine, its molecular architecture incorporates a sterically encumbered quaternary tert-butyl side chain flanked by a chiral alpha-carbon, an orthogonal tert-butoxycarbonyl (Boc) protected primary amino moiety, and a reactive carboxylic acid terminus; the extreme steric crowding imparted by the bulky hydrophobic tert-butyl group establishes rigid conformational constraints along the peptide main chain, promoting bioactive secondary conformations that exhibit enhanced nanomolar binding affinity within catalytic enzyme clefts; simultaneously, this rigid quaternary steric shielding effectively blocks enzymatic recognition and cleavage by endogenous carboxypeptidases, extending systemic plasma half-life and in vivo metabolic stability. In commercial antiviral API production, it functions as the foundational chiral building block for the synthesis of blockbuster HIV protease inhibitors, most notably atazanavir, as well as critical protease-targeting therapeutics. In targeted oncology drug design, it represents a standard chiral structural component for constructing high-affinity ligands directed against the von Hippel-Lindau (VHL) E3 ubiquitin ligase in PROTAC chimeras. In chemical peptide synthesis, the Boc protecting group prevents unwanted side reactions and oligomerization during carboxyl activation, enabling peptide bond formation with broad coupling reagents, followed by clean cleavage under mild acidic conditions without racemizing sensitive stereogenic centers. Furthermore, in asymmetric synthesis, it acts as a chiral precursor for synthesizing rigid bisoxazoline ligands and chiral organocatalysts. Chemical architectures engineered from N-Boc-l-tert-Leucine deliver exceptional optical purity, reproducible reaction kinetics, and broad multi-industry value.